InvestorsHub Logo
Post# of 252658
Next 10
Followers 73
Posts 3426
Boards Moderated 1
Alias Born 04/28/2004

Re: Whalatane post# 206698

Wednesday, 12/07/2016 11:51:04 AM

Wednesday, December 07, 2016 11:51:04 AM

Post# of 252658
PRTO:

"elastin removal with vonapanitase treatment was generally similar when expressed as a percentage reduction, with the exception being that of the basilic vein where at a dose of 1 mg/mL only 30% of elastin (desmosine) was removed after 15 min versus 61–72% for the other vein types. "



Please understand I'm not saying the veins are *identical*. What I'm saying is that if all of these considerations ("sicker" vs "healthier" vs "comorbidities) make an impact on the way a relatively simple enzyme digests elastin when dripped on a vessel, then why are none of the underlying surrogates for improved AVF impacted?

Vein diameter data, blood flow rate and hemodynamically significant stenosis are all unchanged with treatment of RCF or BCF. So if the underlying mechanics of the AVF are unchanged, how do you reconcile a magical subgroup popping out of the data?
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.